

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock code: 1093)**

## **VOLUNTARY ANNOUNCEMENT**

### **DRUG REGISTRATION APPROVAL OF THE GROUP'S “PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)”**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Paclitaxel for Injection (albumin-bound)” (the “**Product**”) developed by the Group has been granted drug registration approval by the China Food and Drug Administration of the People’s Republic of China.

Paclitaxel for injection (albumin-bound) is an antimicrotubule agent indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy or breast cancer relapse within 6 months of adjuvant chemotherapy. As compared to paclitaxel for injection of the conventional formulation, the Product has lesser allergic reactions and faster administration with a higher dose, achieving a more favourable efficacy. Paclitaxel for injection (albumin-bound) was first developed by an overseas pharmaceutical company and was approved by the U.S. FDA in 2005. The drug has already been launched in approximately 27 countries. Other indications approved overseas include treatment of advanced or metastatic non-small cell lung cancer in combination with carboplatin, metastatic pancreatic cancer in combination with gemcitabine and metastatic gastric cancer.

Currently the imported original drug is the only paclitaxel for injection (albumin-bound) available in China. Owing to its high price and good efficacy, the drug has been designated by the government as a drug of urgent clinical need. The Company took the lead to successfully develop the Product and was granted priority review designation by the Centre for Drug Evaluation. The launch of the Product will be able to break the monopoly of the imported drug. With a lower drug

price, the clinical need of the patients will also be better met.

Paclitaxel for injection (albumin-bound) is the Group's second anti-tumour nanodrug. The approval of the Product will further enrich the product portfolio of the Group and contribute to the Group's development in the oncology field.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 12 February 2018

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Jinxu, Mr. WANG Zhenguo, Mr. LU Hua, Mr. LI Chunlei and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*